Provided by Tiger Trade Technology Pte. Ltd.

Dynavax

15.50
0.0000
Volume:- -
Turnover:- -
Market Cap:1.77B
PE:-43.12
High:15.50
Open:15.50
Low:15.50
Close:15.50
52wk High:15.73
52wk Low:9.20
Shares:114.00M
Float Shares:114.00M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3595
EPS(LYR):0.2000
ROE:-7.14%
ROA:1.20%
PB:3.31
PE(LYR):77.50

Loading ...

Company Profile

Company Name:
Dynavax
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.